Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2018

Open Access 01-12-2018 | Review

Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis

Authors: Feng Xu, Lu-Lu He, Luan-Qing Che, Wen Li, Song-Min Ying, Zhi-Hua Chen, Hua-Hao Shen

Published in: Critical Care | Issue 1/2018

Login to get access

Abstract

Background

Aerosolized antibiotics have been proposed as a novel and promising treatment option for the treatment of ventilator-associated pneumonia (VAP). However, the optimum aerosolized antibiotics for VAP remain uncertain.

Methods

We included studies from two systematic reviews and searched PubMed, EMBASE, and Cochrane databases for other studies. Eligible studies included randomized controlled trials and observational studies. Extracted data were analyzed by pairwise and network meta-analysis.

Results

Eight observational and eight randomized studies were identified for this analysis. By pairwise meta-analysis using intravenous antibiotics as the reference, patients treated with aerosolized antibiotics were associated with significantly higher rates of clinical recovery (risk ratio (RR) 1.21, 95% confidence interval (CI) 1.09–1.34; P = 0.001) and microbiological eradication (RR 1.42, 95% CI 1.22–1.650; P < 0.0001). There were no significant differences in the risks of mortality (RR 0.88, 95% CI 0.74–1.04; P = 0.127) or nephrotoxicity (RR 1.00, 95% CI 0.72–1.39; P = 0.995). Using network meta-analysis, clinical recovery benefits were seen only with aerosolized tobramycin and colistin (especially tobramycin), and microbiological eradication benefits were seen only with colistin. Aerosolized tobramycin was also associated with significantly lower mortality when compared with aerosolized amikacin and colistin and intravenous antibiotics. The assessment of rank probabilities indicated aerosolized tobramycin presented the greatest likelihood of having benefits for clinical recovery and mortality, and aerosolized colistin presented the best benefits for microbiological eradication.

Conclusions

Aerosolized antibiotics appear to be a useful treatment for VAP with respect to clinical recovery and microbiological eradication, and do not increase mortality or nephrotoxicity risks. Our network meta-analysis in patients with VAP suggests that clinical recovery benefits are associated with aerosolized tobramycin and colistin (especially tobramycin), microbiological eradication with aerosolized colistin, and survival with aerosolized tobramycin, mostly based on observational studies. Due to the low levels of evidence, definitive recommendations cannot be made before additional, large randomized studies are carried out.
Appendix
Available only for authorised users
Literature
1.
Kollef MH. What is ventilator-associated pneumonia and why is it important? Respir Care. 2005;50(6):714–21. discussion 721-714PubMed
2.
Ehrmann S, Chastre J, Diot P, Lu Q. Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care. Ann Intensive Care. 2017;7(1):78.CrossRefPubMedPubMedCentral
3.
Palmer LB. Aerosolized antibiotics in critically ill ventilated patients. Curr Opin Crit Care. 2009;15(5):413–8.CrossRefPubMed
4.
Zampieri FG, Nassar AP Jr, Gusmao-Flores D, Taniguchi LU, Torres A, Ranzani OT. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Critical Care. 2015;19:150.CrossRefPubMedPubMedCentral
5.
Sole-Lleonart C, Rouby JJ, Blot S, Poulakou G, Chastre J, Palmer LB, Bassetti M, Luyt CE, Pereira JM, Riera J, et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology. 2017;126(5):890–908.CrossRefPubMed
6.
7.
Jiang P, Lv Q, Lai T, Xu F. Does hypomagnesemia impact on the outcome of patients admitted to the intensive care unit? A systematic review and meta-analysis. Shock. 2017;47(3):288–95.CrossRefPubMed
8.
Du F, Jiang P, He S, Song D, Xu F. Antiplatelet therapy for critically ill patients: a pairwise and Bayesian network meta-analysis. Shock. 2018;49(6):616–24.CrossRefPubMed
9.
Ghannam DE, Rodriguez GH, Raad II, Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis. 2009;28(3):253–9.CrossRefPubMed
10.
Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis. 2010;51(11):1238–44.CrossRefPubMed
11.
Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect. 2010;16(8):1230–6.CrossRefPubMed
12.
Perez-Pedrero MJ, Sanchez-Casado M, Rodriguez-Villar S. Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Int. 2011;35(4):226–31.
13.
Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother. 2012;18(6):872–7.CrossRefPubMed
14.
Doshi NM, Cook CH, Mount KL, Stawicki SP, Frazee EN, Personett HA, Schramm GE, Arnold HM, Murphy CV. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol. 2013;13(1):45.CrossRefPubMedPubMedCentral
15.
Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, Spanu T, Antonelli M. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest. 2013;144(6):1768–75.CrossRefPubMed
16.
Migiyama Y, Hirosako S, Tokunaga K, Migiyama E, Tashiro T, Sagishima K, Kamohara H, Kinoshita Y, Kohrogi H. Aerosolized tobramycin for Pseudomonas aeruginosa ventilator-associated pneumonia in patients with acute respiratory distress syndrome. Pulm Pharmacol Ther. 2017;45:142–7.CrossRefPubMed
17.
Le Conte P, Potel G, Clementi E, Legras A, Villers D, Bironneau E, Cousson J, Baron D. Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study. Presse Med. 2000;29(2):76–8.PubMed
18.
Hallal A, Cohn SM, Namias N, Habib F, Baracco G, Manning RJ, Crookes B, Schulman CI. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect. 2007;8(1):73–82.CrossRef
19.
Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother. 2010;65(12):2645–9.CrossRefPubMed
20.
Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;184(1):106–15.CrossRefPubMed
21.
Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, Garcia MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012;38(2):263–71.CrossRefPubMed
22.
Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med. 2014;189(10):1225–33.CrossRefPubMed
23.
Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6(1):26.CrossRefPubMedPubMedCentral
24.
Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, Boulain T, Ivanyi Z, Janos G, Garot D, et al. A randomized trial of the amikacin Fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial. Chest. 2017;151(6):1239–46.CrossRefPubMed
25.
Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care. 2012;57(8):1226–33.CrossRefPubMed
26.
Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138(6):1333–9.CrossRefPubMed
27.
Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE. Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med. 2012;6(5):533–55.CrossRefPubMed
28.
Zhang C, Berra L, Klompas M. Should aerosolized antibiotics be used to treat ventilator-associated pneumonia? Respir Care. 2016;61(6):737–48.CrossRefPubMed
29.
Poulakou G, Matthaiou DK, Nicolau DP, Siakallis G, Dimopoulos G. Inhaled antimicrobials for ventilator-associated pneumonia: practical aspects. Drugs. 2017;77(13):1399–412.CrossRefPubMed
30.
Elman M, Goldstein I, Marquette CH, Wallet F, Lenaour G, Rouby JJ. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology. 2002;97(1):199–206.CrossRefPubMed
31.
Adair CG, Gorman SP, Byers LM, Jones DS, Feron B, Crowe M, Webb HC, McCarthy GJ, Milligan KR. Eradication of endotracheal tube biofilm by nebulised gentamicin. Intensive Care Med. 2002;28(4):426–31.CrossRefPubMed
32.
Mohr AM, Sifri ZC, Horng HS, Sadek R, Savetamal A, Hauser CJ, Livingston DH. Use of aerosolized aminoglycosides in the treatment of gram-negative ventilator-associated pneumonia. Surg Infect. 2007;8(3):349–57.CrossRef
33.
Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis. 2007;58(2):235–40.CrossRefPubMed
34.
Huang JX, Blaskovich MA, Pelingon R, Ramu S, Kavanagh A, Elliott AG, Butler MS, Montgomery AB, Cooper MA. Mucin binding reduces colistin antimicrobial activity. Antimicrob Agents Chemother. 2015;59(10):5925–31.CrossRefPubMedPubMedCentral
35.
Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–29.CrossRefPubMed
Metadata
Title
Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis
Authors
Feng Xu
Lu-Lu He
Luan-Qing Che
Wen Li
Song-Min Ying
Zhi-Hua Chen
Hua-Hao Shen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-018-2106-x

Other articles of this Issue 1/2018

Critical Care 1/2018 Go to the issue

Research

Enteral nutrition feeding in Chinese intensive care units: a cross-sectional study involving 116 hospitals

Commentary

Sepsis is a preventable public health problem

Letter

Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment

Research

Improved empirical antibiotic treatment of sepsis after an educational intervention: the ABISS-Edusepsis study

Research

Delay in antibiotic therapy results in fatal disease outcome in murine pneumococcal pneumonia

Review

The emerging role of the microbiota in the ICU